Issue 80, 2016

A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies

Abstract

A squaramide ester derivative of desferrioxamine B (H3DFO) that is compatible with aqueous solvents and does not induce antibody aggregation is used to attach the siderophore to the antibody trastuzumab. The new conjugates were radiolabeled with zirconium-89 to give complexes that are more resistant to ligand exchange when compared to currently used H3DFO derivatives and result in high quality positron emission tomography images in mouse models of HER2 positive breast cancer.

Graphical abstract: A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies

Associated articles

Supplementary files

Article information

Article type
Communication
Submitted
20 Jul 2016
Accepted
19 Aug 2016
First published
19 Aug 2016

Chem. Commun., 2016,52, 11889-11892

A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies

S. E. Rudd, P. Roselt, C. Cullinane, R. J. Hicks and P. S. Donnelly, Chem. Commun., 2016, 52, 11889 DOI: 10.1039/C6CC05961A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements